ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Bleeding Risk Prediction in Non-Valvular Atrial Fibrillation: Comparing Risk Scores in Apixaban- and Rivaroxaban-Treated Patients.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- DOAC Score Versus HAS-BLED and ORBIT for Predicting Bleeding Events in Atrial Fibrillation on Direct Oral Anticoagulants.Clinical cardiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study aimed to evaluate the ability of seven bleeding risk assessment tools to predict bleeding events in patients with apixaban or rivaroxaban.MethodsA retrospective analysis was conducted on 313 NVAF patients (apixaban: n = 164; rivaroxaban: n = 149) with at least one year of follow-up at a tertiary hospital in Malaysia. Bleeding risk scores were calculated at treatment initiation using original definitions. Bleeding events were defined according to ISTH criteria. Predictive performance was assessed via area under the receiver operating characteristic (AUROC) curves, with good diagnostic accuracy defined as AUROC ≥ 0.7. Subgroup analyses by age and sex were also performed.ResultsOverall bleeding incidence was 12.46%. Among rivaroxaban users, ORBIT (AUROC 0.68), RE-LY (0.66), and HEMORR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.